证券代码：001367 证券简称：海森药业 公告编号：2025-053 浙江海森药业股份有限公司 关于 2024 年限制性股票激励计划预留授予登记完成的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 重要内容提示： 限制性股票预留授予日：2025年9月11日 预留授予的限制性股票上市日：2025年10月30日 预留授予的限制性股票登记数量：42.4760万股，占本激励计划预留授予 日公司股本总额的0.2796%。 限制性股票来源：公司向激励对象定向发行的本公司A股普通股股票 根据中国证券监督管理委员会《上市公司股权激励管理办法》、深圳证券交 易所、中国证券登记结算有限责任公司深圳分公司的有关规定，浙江海森药业股 份有限公司（以下简称"公司"）完成了2024年限制性股票激励计划（以下简称 "本次激励计划"或"本激励计划"）预留授予登记工作，现将有关事项说明如 下： 一、本次激励计划已履行的相关审批程序 （一）2024年9月12日，公司召开第三届董事会第七次会议，审议通过了《关 于<浙江海森药业股份有限公司2024年限制性股票激励计划（草案）>及其摘要 的议 ...

Core Insights - The company, Haisen Pharmaceutical (001367.SZ), reported a strong performance in its Q3 2025 financial results, achieving a revenue of 117 million yuan, representing a year-on-year growth of 6.74% [1] Group 1: Company Performance - Haisen Pharmaceutical maintains a stable operational performance despite a complex external environment [1] - The company has a diverse product portfolio, including active pharmaceutical ingredients (APIs) and solid formulations, with leading products such as Paroxetine Hydrochloride and Amikacin side-chain PHBA [1] - The market share for Sucralfate is approximately 60%, ranking first internationally, while the domestic market share for Amikacin side-chain PHBA and Methylsulfonylmethane is also over 60% [1] Group 2: Market and Expansion - The company has sufficient market orders for its main products, indicating a robust supply and demand situation [1] - Haisen Pharmaceutical is actively advancing the construction of a new green and intelligent pharmaceutical production base to enhance production capacity [1] - The company is expanding its market presence through a global layout, optimizing its market structure [1] Group 3: Strategic Partnerships - The company has established long-term cooperative relationships with several strategic partners, some lasting over 20 years, which has built a solid foundation for collaboration [2] - Haisen Pharmaceutical has formed stable partnerships with leading global clients, including TEVA, across multiple products [2]

Core Viewpoint - Haosen Pharmaceutical reported a revenue of 359 million yuan for the first three quarters of 2025, marking a year-on-year growth of 12.13%, and a net profit attributable to shareholders of 88 million yuan, with a growth of 1.45% [1] Financial Performance - The total assets of Haosen Pharmaceutical reached 1.569 billion yuan, reflecting a year-on-year increase of 5.55% [1] - Revenue growth of 12.13% and net profit growth of 1.45% indicate stable financial performance despite market challenges [1] Innovation and R&D - The company prioritizes technological innovation and has established a strong mechanism for innovation through collaborations with universities and research institutions [1] - Haosen Pharmaceutical holds 25 authorized patents, with 23 being invention patents, covering key preparation processes and equipment [1] - The collaboration with Hangzhou Haosen Drug Research Institute has enhanced R&D efficiency and market responsiveness [1] Market Expansion - The company is actively expanding into high-end markets in the Americas and Europe, enhancing brand influence through participation in international exhibitions [1] - Establishing long-term partnerships with leading global clients like TEVA has strengthened its position in the global pharmaceutical supply chain [1] Industry Outlook - Haosen Pharmaceutical anticipates continued growth in the emerging pharmaceutical sector, viewing the bulk procurement of chemical drugs as an opportunity for raw material pharmaceutical companies [1]

Core Insights - The company reported a revenue of 116,781,310.01 yuan for the third quarter of 2025, representing a year-on-year increase of 6.74% [2] - The net profit attributable to shareholders of the listed company was 27,415,463.98 yuan, showing a year-on-year decrease of 5.17% [2] Financial Performance - Revenue for Q3 2025: 116.78 million yuan, up 6.74% year-on-year [2] - Net profit for Q3 2025: 27.42 million yuan, down 5.17% year-on-year [2]

其中第三季度，公司营业收入为1.17亿元，同比增长6.74%；归属净利润为2741.55万元，同比下降 5.17%。 北京商报讯（记者 丁宁）10月21日晚间，海森药业（001367）发布2025年三季报显示，公司前三季度 实现营业收入3.59亿元，同比增长12.13%；归属净利润8820.96万元，同比增长1.45%。 ...

格隆汇10月21日丨海森药业(001367.SZ)公布三季度报告，前三季营业收入3.59亿元，同比增长12.13%， 归属于上市公司股东的净利润8820.96万元，同比增长1.45%，归属于上市公司股东的扣除非经常性损益 的净利润8475.8万元，同比下降1.56%。 ...

（记者 曾健辉） 每经AI快讯，海森药业10月21日晚间发布公告称，公司第三届第十七次董事会会议于2025年10月21日 在公司会议室以现场方式召开。会议审议了《关于公司2025年第三季度报告的议案》等文件。 每经头条（nbdtoutiao）——展望"十五五"|专访贺铿：必须改变以往将资金过度集中于房屋建设和基础 设施建设的倾向，更加突出民生领域投入 ...

Core Viewpoint - Haosen Pharmaceutical (001367.SZ) reported a year-on-year revenue increase of 12.13% for the first three quarters of 2025, reaching 359 million yuan [1] Financial Performance - The company's net profit attributable to shareholders was 88.21 million yuan, reflecting a year-on-year growth of 1.45% [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was 84.76 million yuan, showing a year-on-year decrease of 1.56% [1] - Basic earnings per share stood at 0.59 yuan [1]

智通财经APP讯，海森药业(001367.SZ)发布2025年三季度报告，该公司前三季度营业收入为3.59亿元， 同比增长12.13%。归属于上市公司股东的净利润为8820.96万元，同比增长1.45%。归属于上市公司股东 的扣除非经常性损益的净利润为8475.8万元，同比减少1.56%。基本每股收益为0.59元。 ...

南财智讯10月21日电，海森药业公告，2025年前三季度公司实现营业收入3.59亿元，同比增长12.13%； 归属于上市公司股东的净利润0.88亿元，同比增长1.45%。基本每股收益0.59元，同比增长1.72%。 ...